Diabetes drug market has expanded year by year, and new hypoglycemic drugs have emerged

 Diabetes is one of the common chronic diseases, mainly divided into type 1 diabetes, type 2 diabetes, gestational diabetes and other types of diabetes
.
With the increase in the prevalence of diabetes in China, the improvement of people's living standards and medical standards, the scale of China's diabetes drug market is expanding year by year.
It is estimated that by 2022, the market size will be close to 43.
7 billion yuan
.
Speaking of hypoglycemic drugs, you may think of traditional drugs such as metformin and insulin.
In fact, many new hypoglycemic drugs have emerged in recent years, bringing good news to patients.
Recently, some pharmaceutical companies have introduced the field of diabetes drugs.
Good news
.
China Biopharmaceuticals Saxagliptin Tablets Obtained Drug Registration Certificate Recently, China Biopharmaceuticals issued an announcement that Saxagliptin Tablets (trade name: Besnin) developed by the Group for the treatment of type 2 diabetes has been granted drug registration by the State Drug Administration The certificate is the second domestic approval for this kind of generic drug, and it is deemed to have passed the generic drug quality and efficacy consistency evaluation
.
Saxagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, which can prolong endogenous glucagon-like peptide-1 (GLP-1) by inhibiting DPP-4 And the action time of glucose-dependent insulinotropic polypeptide (GIP) to regulate blood sugar, mainly used for the treatment of type 2 diabetes
.
Compared with traditional hypoglycemic drugs, the advantages of DPP-4 inhibitors are that they do not increase the risk of hypoglycemia, have a neutral effect on body weight, and have good cardiovascular safety
.
Besnin's approval for listing will further enrich and improve the Group's product line layout in the diabetes field
.
It is understood that abundant clinical trials have shown that saxagliptin tablets have advantages in terms of safety, effectiveness, quality controllability, etc.
; its clinical positioning is clear and widely used, and it has been included in the National Medical Insurance Catalog (Category B) As an anti-diabetic drug, it will have a very broad market prospect
.
Hua Medicine's new diabetes drug completes phase III clinical trials, which is expected to "cure both the symptoms and the root cause".
Recently, Hua Medicine announced that the phase III clinical study of the new drug dorzagliatin for the treatment of type 2 diabetes has ended, and its 52-week core data showed good efficacy and safety.
sex
.
It is understood that this new drug can not only effectively reduce the blood glucose index of diabetic patients, but also improve the islet function index, which is expected to achieve the effect of "treatment of both symptoms and root causes"
.
Currently, the phase III clinical study of dorzagliatin for diabetic patients whose metformin has failed adequate treatment is still underway
.
After completing this study, Hua Medicine will submit a new drug listing application to the State Food and Drug Administration
.
According to reports, dorzagliatin is a glucokinase activator
.
Glucokinase is the blood sugar "sensor" in the human body.
When the blood sugar is high, it will issue instructions to promote insulin secretion; when the blood sugar is low, it will also issue instructions to promote the secretion of glucagon and play a role in regulating blood glucose homeostasis
.
The pathogenesis of type 2 diabetes is that insulin resistance causes a decrease in pancreatic islet function, which leads to an increase in blood sugar
.
The glucokinase in the patient's body often decreases in expression or function, and cannot sensitively "perceive" the increase or decrease in blood sugar
.
Tonghua Dongbao won the first oral hypoglycemic drug Recently, Tonghua Dongbao Pharmaceutical Co.
, Ltd.
received the "Drug Registration Certificate" for sitagliptin phosphate tablets approved and issued by the State Drug Administration
.
Information shows that sitagliptin phosphate tablets have been approved for the market, becoming Tonghua Dongbao's first oral hypoglycemic drug, and it also marks Tonghua Dongbao's official entry into the oral hypoglycemic drug market
.
It is understood that sitagliptin phosphate is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor.
Compared with traditional hypoglycemic drugs, this type of drug does not increase the risk of hypoglycemia, It has the advantages of neutral influence on body weight and good cardiovascular safety
.
11 new class 1 hypoglycemic drugs such as Hengrui, Xinlitai, and Yuandong are on the way.
According to relevant statistics, in the field of research and development of domestic class 1 new drugs for DPP-4 inhibitors, there are currently 11 innovative drugs under development
.
Among them, Hengrui Medicine’s Repagliptin Phosphate titles submitted an NDA; Xinlitai, CSPC, Hisco, and Shengshitaike’s DPP-4 inhibitors are all in phase III clinical trials; Yuandong Biological, Zhengdatian Qing Pharmaceutical Group’s DPP-4 inhibitor is in phase II clinical trials
.
It is reported that Hengrui Medicine is expected to win the first domestically produced DPP-4 inhibitor Class 1 new drug
.
In addition, Haisco's HSK7653 is expected to be submitted to the NDA in 2022 and be approved for listing in 2023
.
Yuandong Biological's Yodagliptin tablets are expected to complete Phase II clinical trials in 2021 and submit an NDA in 2025
.